Press Room

Bioprocessing Summit Europe

Start
Tuesday, March 20, 2018 - 00:00
End
Thursday, March 22, 2018 - 00:00
Location: Lisbon, Portugal
Booth Number: 9

Bioprocessing Summit Europe brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for today's bioprocessing needs. 

Hovione is present at the Bioprocessing Summit Europe with a Booth (# 9) and with a presentation by Márcio Temtem.

 

HOVIONE PRESENTATION

Spray drying - a viable alternative to biopharmaceuticals?

Date/Time: Thursday, March 22nd, 9:30

Room: White Plains 5

Presentation abstract:

Spray drying is presently one of the most exciting technologies in the pharmaceutical industry with several commercial products approved each year.

The relevance of the technology is in part explained by the fact it is a scalable drying process suitable to convert liquid streams into dry powders with a broad range of properties. Such flexibility led to its application in a variety of pharmaceutical formulations: from very fine powders for inhalation to large particles for direct compression, or from solid dispersions for enhanced bioavailability to microcapsules for controlled release. The process considers the fine spraying of a liquid into a hot gas, evaporating, drying and collecting the solid particles from the gas stream. The process is very fast and product-gas contact very short. Due to the intensive evaporative during the drying, temperature in the droplet remains relatively low, making the process suitable for the processing of thermos labile materials like biopharmaceuticals (e.g. proteins, peptides or antibodies).  In this talk the authors will present examples of such processes and the advantages of spray drying over conventional technologies.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us.

 

Our colleague, Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development
 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026